|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Altogether, our data indicate that T cell-specific restoration of ATM activity or allogeneic hematopoietic stem cell transplantation may prevent lymphomagenesis in A-T patients.
|
31690822 |
2020 |
|
Leukemogenesis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ATM defect in these patients could therefore impair the normal regulation of EBV latency in B-cells, thus promoting lymphomagenesis.
|
30662441 |
2018 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate in this study that when T cells are removed as targets for lymphomagenesis and as mediators of immune surveillance, ATM-deficient mice exclusively develop early-onset immunoglobulin M(+) B-cell lymphomas that do not transplant to immunocompetent mice and that histologically and genetically resemble the activated B cell-like (ABC) subset of human diffuse large B-cell lymphoma (DLBCL).
|
26400962 |
2015 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together these findings define a synergistic function of ATM and CyclinD1 in pre-GC B-cell proliferation and lymphomagenesis and provide a prototypic animal model to study the pathogenesis of human MCL.
|
25676421 |
2015 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis.
|
23318439 |
2014 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies have shown that MYC-driven lymphomagenesis is associated with mammalian target of rapamycin (mTOR) activation and a MYC-evoked DNA damage response (DDR) transduced by phosphatidylinositol-3-kinase (PI3K)-related kinases (DNA-PK, ATM, and ATR).
|
23403624 |
2013 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ATM gene alterations have been described in various lymphoproliferative malignancies suggesting that ATM contributes to lymphomagenesis.
|
18261794 |
2008 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the ATM protein is more strongly correlated with PCNS DLBCL lymphomagenesis than with non-CNS DLBCLs, especially in germinal center B-cell-like subtypes demonstrating low Ki-67 labeling indexes and low Bcl-2 expression.
|
17516749 |
2007 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ATM gene alterations and impaired ATM protein expression have been described in various adult lymphoproliferative malignancies, suggesting that ATM contributes to lymphomagenesis.
|
16631465 |
2006 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ATM-dependent DNA damage surveillance in T-cell development and leukemogenesis: the DSB connection.
|
16448540 |
2006 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) genes are responsive genes for DNA damage, therefore potential involvement of these genes in PAL lymphomagenesis was examined in eight PAL cell lines and clinical samples from five cases.
|
15696190 |
2005 |
|
Leukemogenesis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Inherited biallelic mutations of the ATM (ataxia-telangiectasia mutated) gene cause ataxia-telangiectasia, a rare autosomal recessive disorder associated with a high incidence of childhood leukaemias and lymphomas, suggesting that ATM gene alterations may be involved in lymphomagenesis.
|
14628072 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our observations lend further support to the postulated contribution of ATM in lymphomagenesis.
|
12673804 |
2003 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, patients with ATM deficiency had significantly shorter survival times (35.66 versus 97.3 months; P = 0.003) and more aggressive disease, suggesting that ATM is involved in the leukemogenesis of B-CLL.
|
9788599 |
1998 |